Chinese expert consensus on the application of live combined Bifidobacterium , Lactobacillus , and Enterococcus powder/capsule in digestive system diseases (2021)
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16195 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Jingyuan Fang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Digestive System Diseases, Probiotics. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Background and Aim Disturbance of gut microbiota is associated with pathological change in multiple diseases. Probiotics can improve symptoms and exert clinical effects via regulation of gastrointestinal microecological environments, and a probiotic product commonly dispensed by Chinese physicians is a combination of live Bifidobacterium , Lactobacillus , and Enterococcus in powder/capsule form. It contains three strains—of Bifidobacterium longum , Lactobacillus acidophilus , and Enterococcus faecalis —which can act synergistically to balance the microbiome, regulate immunity, and repair the gut barrier. Although this product has been proven safe and effective in clinical practice, uncertainty remains regarding its use to treat digestive system diseases. To date, there have been no reference standards to guide clinical practice and no relevant expert consensus on this product, in China.
Methods
Following a literature search, evidence was graded and classified according to the grading of recommendations assessment, development, and evaluation (GRADE) system and consensus was secured from a panel of 52 experts.
Results
An expert consensus has been formed, on the clinical application of live combined Bifidobacterium , Lactobacillus , and Enterococcus in various digestive system diseases, to provide reference for its clinical use.
Conclusions
Bifidobacterium triple viable powder/capsule may offer benefits, by regulating the balance of intestinal microecology. It can be used for the treatment and prevention of various digestive system diseases with good overall safety; further research is needed to confirm its application in other contexts. The recommendations in this consensus will be confirmed or refined in light of future research and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Gastroenterology, Shanghai Changzheng Hospital, Shanghai, China.
ORCID-Profile: Jingyuan Fang, Weifen Xie
Zitieren
APA
Fang, J., Yang, Y., & Xie, W. (2023). Chinese expert consensus on the application of live combined Bifidobacterium , Lactobacillus , and Enterococcus powder/capsule in digestive system diseases (2021). Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16195
Vancouver
Fang J, Yang Y, Xie W. Chinese expert consensus on the application of live combined Bifidobacterium , Lactobacillus , and Enterococcus powder/capsule in digestive system diseases (2021). Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16195
BibTeX
@article{Fang2023,
author = {Fang, Jingyuan and Yang, Yunsheng and Xie, Weifen},
title = {Chinese expert consensus on the application of live combined Bifidobacterium , Lactobacillus , and Enterococcus powder/capsule in digestive system diseases (2021)},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16195}
}
EUVIMED